title: Life-Threatening Abnormal Behavior Incidence in 10-19 Year Old Patients Administered Neuraminidase Inhibitors.
abstract: Much discussion has surrounded the association between the administration of neuraminidase inhibitors (NI) and severe abnormal behaviors, including sudden running away and jumping from a high place, which can be life-threatening if no one intervenes. Using data on the number of abnormal behaviors and patients who had been prescribed NI in Japan, we calculated the incidence rate of severe abnormal behaviors among influenza patients who had been prescribed NI. Then, we evaluated the relative risk between the four types of NI on severe abnormal behavior. We found no significant difference in the incidence rates of abnormal behavior by the type of NI. Results implicate that the current policy of package inserts, which warn physicians that patients who were administered ANY type of NI might exhibit abnormal behavior, seems to be appropriate.
authors.affiliation: Graduate School of Pharmacy, Nihon University, Funabashi, Chiba, Japan.
authors.forename: Yuuki
authors.initials: Y
authors.lastname: Nakamura
authors.affiliation: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
authors.forename: Tamie
authors.initials: T
authors.lastname: Sugawara
authors.affiliation: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ohkusa
authors.affiliation: National Hospital Organization Mie National Hospital, Tsu, Mie, Japan.
authors.forename: Kiyosu
authors.initials: K
authors.lastname: Taniguchi
authors.affiliation: Fukuoka Welfare Center for the Disabled, Fukuoka, Fukuoka, Japan.
authors.forename: Chiaki
authors.initials: C
authors.lastname: Miyazaki
authors.affiliation: International University of Health and Welfare, Ohtawara, Tochigi, Japan.
authors.forename: Mariko
authors.initials: M
authors.lastname: Momoi
authors.affiliation: Kawasaki City Institute for Public Health, Kawasaki, Kanagawa, Japan.
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Okabe
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003617:Dangerous Behavior; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015994:Incidence; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D007564:Japan / Q000453:epidemiology; D008297:Male; D001523:Mental Disorders / Q000453:epidemiology* / Q000209:etiology*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D012621:Seasons; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D009439:Neuraminidase